Bailly E, Ville S, Blancho G, et al. - In the French multicenter double‐blind RITUX‐ERAH study, 38 patients with antibody‐mediated rejection (ABMR) in the first year of renal transplantation were included and were provided plasma exchanges, intravenous immunoglobulins, and corticosteroids. In addition, the patients were randomly assigned to receive either rituximab or placebo infusion at day 5. Researchers performed an evaluation of the 7‐year outcomes of the RITUX‐ERAH study participants. Patients receiving rituximab did not differ from those receiving placebo in terms of death‐censored kidney allograft survival and renal function 7 years after ABMR. Further, no statistically significant difference in the incidence of infectious or neoplastic complications was observed, but to be noted, seven cancers developed in six patients treated with rituximab (mean period of 44 months post‐ABMR). This cohort study did not suggest any benefit of providing rituximab in addition to plasma exchanges, intravenous immunoglobulins, and steroids 7 years after ABMR.